Drug intelligence / Profile preview

Sabufen

Development stage: Unknown
Lead developer: S-INFINITY
Modality: Small Molecules
Administration: Oral

Overview

Sabufen is a branded generic version of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, developed and marketed by S.A. Infinity Europe (S-INFINITY). It is indicated for the management of pain and inflammation. As an NSAID, Sabufen works by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are responsible for the synthesis of prostaglandins. Prostaglandins are key lipid mediators that promote pain, fever, and inflammatory responses in the body. By reducing prostaglandin production, Sabufen provides analgesic and anti-inflammatory therapeutic effects.

Brand names: Sabufen
Other names: ibuprofen

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Sabufen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sabufen.

Explore the full profile